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Data from human studies and animal experiments indicate a dominant role of T-cells over antibodies in controlling acute Lassa virus
infection and providing immunity to reinfection. Knowledge of the epitopes recognized by T-cells may therefore be crucial to the
development of a recombinant Lassa virus vaccine. In order to study human T-cell reactivity to the most conserved structural protein of Lassa
virus, the glycoprotein 2 (GP2), seven GP2-specific CD4+ T-cell clones (TCCs) were generated from the lymphocytes of a Lassa antibody
positive individual. All TCC displayed high specific proliferation, showed DR-restriction, and produced IFN-g upon stimulation with
recombinant GP2. The epitope of four of the clones was localized to a short stretch of 13 amino acids located in the N-terminal part of GP2
(aa 289–301, numbering according to sequence of GPC). This epitope is conserved in all strains of Lassa virus and lymphocytic
choriomeningitis virus (LCMV), shows >90% similarity in all New World arenaviruses of clade B, and overlaps with the proposed fusion
domain of GP2. Peptides with conservative aa exchanges, as they naturally occur in the epitope 289–301 of the Old World arenavirus
Mopeia and some New World arenaviruses, continued to effectively stimulate the Lassa-GP2-specific T-cell clones tested. The finding of a
human T-helper cell epitope, which is highly conserved between Old and New World arenaviruses, is of importance for the design of
arenavirus vaccines.
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Introduction recombinant vaccinia viruses or alphavirus repliconsLassa virus is endemic in certain parts of West Africa and
causes an estimated 150000 clinical cases of a systemic
viral illness per year, with a mortality of 10–15% (McCor-
mick et al., 1987). As a highly infectious hemorrhagic fever
virus for which no vaccine is available, it is listed as a
category A biological weapon agent (Klotz et al., 2002).
Experimental immunization of monkeys or guinea pigs with0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: j.termeulen@crucell.com (J.T. Meulen).expressing Lassa virus structural proteins has been shown
to protect 85–100% of animals against a lethal challenge
(Fisher-Hoch et al., 2000; Pushko et al., 2001). It was also
shown that expression of both glycoproteins of Lassa virus
(GP1 and GP2) by the recombinant vector is necessary and
sufficient for protection of nonhuman primates (Fisher-Hoch
et al., 2000). In the guinea pig model of Lassa fever,
adoptive spleen cell transfer of animals immunized with
different Old World arenaviruses protected naive animals
from homologous and heterologous infection, whereas
transfer of serum did not and the protection was shown to
be conferred by CD8+ cytotoxic cells (Jahrling and Peters,
1986). However, mice immunized with a recombinant
Table 1
Proliferative response of PBMC from Lassa virus antibody positive and
negative individuals
No. Lassa-antibody Proliferative response toa PIb
Sex/age IIFc ELISAd recGP2 recNP NEG PHA recGP2 recNP
28 M/45 1:20 5.3 4082 24551 54 37798 75,3 452,9
1 M/27 neg neg 11487 14975 342 70918 33,5 43,7
11 M/65 neg neg 3143 7456 256 68573 29,2 12,3
8 M/8 neg 2.6 10736 6838 506 74253 21,2 13,5
18 F/40 neg 2.6 3838 4646 218 38749 17,6 21,3
10 F/15 neg neg 1408 2354 92 62481 15,3 25,6
5 M/58 neg neg 3046 7699 386 37988 7,8 19,8
a Units are [3H]thymidine counts per minute. NEG, negative control = cell
culture medium.
b Proliferation index. Statistically significant proliferation (definition see
results).
c IIF, indirect immunofluorescence.
d IgG–ELISA. Ratio ODpositive control well/ODnegative control well at a serum
dilution of 1:100.
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were protected against LCMV infection exclusively by GP2-
specific cytotoxic CD4+ T-cells in the absence of N anti-
bodies (La Posta et al., 1993), and it was speculated that this
type of cells could generally be involved in cross-protective
immunity against heterologous arenavirus infections.
The protection induced by recombinant Lassa virus
vaccines is rather short-lived and independent of neutraliz-
ing (N) antibodies, because these are detected neither after
immunization nor after challenge (Fisher-Hoch et al., 2000;
Pushko et al., 2001). Similar data pointing to a prominent
role of T-cell immunity for the control of this disease have
also come from human studies. Humans develop a very
delayed and low N antibody response after natural infection
with Lassa virus (Tomori et al., 1987), which seems to be
strain specific. Furthermore, treatment of Lassa fever
patients with human immune plasma has generally not
yielded convincing results (Jahrling et al., 1985). One study
reported a strong memory CD4+ T-cell response against the
nucleoprotein of Lassa virus in healthy Lassa-antibody
seropositive as well as seronegative persons from an
endemic region, who had not been reinfected with the virus
for at least 6 years (ter Meulen et al., 2000). Because any
recombinant Lassa virus vaccine will have to protect
against different strains of the virus, presumably on the
basis of a robust T-cell immunity alone, we studied the T-
cell response against the most conserved structural protein
of Lassa virus and all arenaviruses, the glycoprotein 2
(GP2).Results
Peripheral blood mononuclear cells of seven lymphocyte
donors proliferate in response to both recombinant GP2
and NP of Lassa virus (JOS)
Seven individuals with statistically significant lympho-
cyte proliferation in response to stimulation with both
recombinant NP and GP2 of Lassa virus were identified
(Table 1). Three of seven (42.8%) lymphocyte donors had
anti-Lassa antibodies detectable by either indirect immuno-
fluorescence (IIF) or ELISA (Table 1).
Specific proliferation was observed both in antibody
positive and antibody negative donors. From donor #28,
who showed the strongest proliferation response both to
GP2 and NP, the GP2-specific CD4+ T-cell clones (TCCs)
were generated in this study. From the same donor, NP-
specific CD4+ T-cell clones have been generated previously
(ter Meulen et al., 2000).
GP2-specific T-cell clones are DR-restricted and belong to
Th1-phenotype
Primary and secondary cultures of peripheral blood
mononuclear cell (PBMC) from donor #28 were used togenerate TCC. In several rounds of cloning, >200 TCCs
were generated, 42 of which were found to react specifi-
cally with recombinant GP2. For seven of these, the
epitopes were mapped, with single peptides showing pro-
liferation indices ranging from 5.8 to 126.4 (Table 2). All
TCCs tested were restricted to HLA-DR, as shown by the
reduction in GP2-specific proliferation when anti-DR anti-
body was added to the cultures (data not shown). All TCC
produced IFN-g (range, 570–2970 pg/ml for stimulation
with phytohemagglutinin [PHA]; range, 293–2776 for
stimulation with GP2 and synthetic peptides), but none
produced IL-4.
Mapping of T-cell epitopes in the GP2 of Lassa virus (JOS)
using TCC
The 21 overlapping peptides that had been synthesized
were first tested for proliferation induction on TCC in four
pools of five peptides each. In a second step, peptides from
proliferation-inducing pools were tested individually. Three
epitopes were found, which in all cases were contained in
two adjacent peptides. They comprise amino acids 23–35
(282–294), 28–40 (289–301), and 135–147 (394–406) of
GP2 (Table 2 and Fig. 1). Numbers in parentheses refer to
the numbering of amino acids as in the glycoprotein
precursor GPC. Of seven clones, four were found to react
with the two overlapping stimulatory peptides P3 and P4
(TCC 38, TCC 53, TCC 90, TCC 139), two with peptides
P18 and P19 (TCC 42, TCC 141), and one with peptides
P2 and P3 (TCC 12, Table 2). Epitopes (282–294) and
(289–301) partially overlap with the presumed fusion
peptide of Lassa virus (Fig. 1, Glushakova et al., 1990)
and epitope (394–406) partially overlaps with a T-cell
epitope in C3H/HeJ (H-2k)-mice, against which LCMV/
Lassa cross-reactive cytotoxic CD4+ T-cells were generated
(La Posta et al., 1993; Fig. 1).
Table 2
Screening of Lassa GP2-specific TCCa for reactivity to overlapping peptides spanning aa 260–427 of the GPCb
# aa Peptide sequence PIc for
TCC-12 TCC-90 TCC-38 TCC-53 TCC-139 TCC-42 TCC-141
NEG 1.0 1.0 1.0 1.0 1.0 1.0 1.0
recGP2 13.9 51.2 10.4 5.9 11.9 34.7 10.0
P2275 – 294 PGGYCLTRWMLIEAELKCFG 23.5
P3282 – 301 RWMLIEAELKCFGNTAVAKC 52.0
P3282 – 301 RWMLIEAELKCFGNTAVAKC 101.4 29.6 126.4 28.1
P4289 – 308 ELKCFGNTAVAKCNEKHDEE 52.3 26.2 67.5 31.1
P18387 – 406 LVSNGSYLNETHFSDDIEQQ 18.2 4.4
P19394 – 413 LNETHFSDDIEQQADNMITE 34.3 5.8
a All TCC are from donor #28.
b Peptides were used in the assay at 1, 0.1, and 0.01 Ag/ml. The two peptides containing the T-cell epitope induced proliferation at all three concentrations
tested. The maximum proliferation found at 1 Ag/ml is shown. The standard deviation was <10%. Amino acids contained in both stimulatory peptides are
boldfaced.
c Proliferation indices (PI) are means of one representative assay, run in triplicate.
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sequences of other Old World and New World arenaviruses
revealed a high degree of conservation for epitope (289–
301) (Table 3). This epitope is 100% identical in all Lassa
strains and highly conserved in all Old World arenaviruses,
showing only two conserved amino acid substitutions. It is
also highly conserved in New World arenaviruses of clade
B and in some of clade A, which comprise the South
American viruses capable of causing hemorrhagic fever in
humans (Guanarito, Sabia, Junin, Machupo viruses) and
North American arenaviruses (Bear Canyon and White-
water Arroyo virus) respectively.Fig. 1. Alignment of human CD4 T-cell epitopes on GP2 of Lassa virus, strain
cleavage motif RRLL is underlined and the presumed fusion peptide (aa 276–298
P19. Numbering of aa according to the sequence of GPC of Lassa virus, strain
overlapping region of two stimulatory peptides. Boldface aa: epitope for cytolyti
presumed transmembrane domain of GP2 is at aa 428 (Genbank accession numbe
AF181853, CSF/AF333969).TCC 53 cross-reacts with epitopes located in the presumed
fusion region of glycoprotein 2 of the Lassa virus (JOS) and
the arenavirus Mopeia (MOP)
Comparison of the JOS epitopes with the homologous
sequences in the glycoprotein 2 of the presumably non-
pathogenic African arenavirus MOP is given in Fig. 2.
Epitope (282–294) shows three nonconserved and one
conserved amino acid substitution (77% homology), where-
as both aa substitutions in epitope (289–301) are of the
conserved type. These two epitopes are located in three
overlapping peptides (P2, P3, and P4), which were synthe-Josiah, with other Lassa virus strains. The glycoprotein precursor (GPC)
, (9)) is boxed. Bold lines indicate stimulatory peptides P2, P3, P4, P18, and
Josiah. Amino acids in italics: presumed T-cell epitopes, contained in the
c mouse CD4+ T-cells, cross-reactive with Lassa and LCMV (17). Start of
rs: Josiah/J04324, AV/AF246121, Nigeria/X52400, 803213/AF181854, LP/
Table 3
Alignment of human CD4 epitopes (282–294; 289–301) in the presumed fusion region of Lassa virus glycoprotein 2 (GP2) with Old and New World
arenaviruses
The overlap of the presumed CD4 epitopes (282–294) and (289–301) is underlined. Viruses marked with HF are significant human pathogens, causing
hemorrhagic fever. Numbers above alignment indicate aa positions in Lassa virus, strain Josiah, GPC. ‘‘*’’ Denotes amino acids identical to Lassa–Josiah, ‘‘:’’
denotes conservative amino acid exchanges. ‘‘$’’ In epitope 282–294, the aa K (position 282) and L (position 286) are R and I in LCMV strains CH-5692 and
CH-5871, the aa D (position 289) is conservatively mutated to E in LCMV-WE and callitrichid hepatitis virus. ‘‘&’’ In epitope 289–301, the amino acid E
(position 298) is conservatively mutated to D in LCMV strains CH-5692 and CH-5871. Genbank accession numbers for viral sequences: Lassa–Josiah
(J04324), LCMV-WE (P07399), Mopeia (M33879), Bear Canyon (AF512833), Tacaribe (NC_004293), White Water Arroyo (AF228063), Guanarito
(AY129247), Sabia (U41071), Cupixi (AF512832), Tamiami (AF512828), Junin (D10072), Machupo (AY129248), Latino (AF512830), Oliveros (U34248),
Allpahuayo (AY081210), Flexal (AF512831), Pirital (AF485262), Parana (AF512829), Pichinde (AF081554).
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eration of TCC 53, the epitope of which is represented by
the overlap of peptides P3 and P4, was nearly equally
stimulated either by JOS-P3/P4 or MOP-P3/P4.
Proliferation of bulk PBMC in response to stimulation with
peptides P2, P3, P4 and comparison with ProPred-predicted
binding motifs
The PBMC from six donors were directly stimulated
with single peptides. Two of the six donors (no. 8, 11)
showed a specific proliferation against the single peptides
P3 and P4 located in the presumed fusion region of GP2
(Fig. 3). Including the donor of the TCC (#28), three of
seven persons (43%) with significant proliferation in re-
sponse to the recombinant Lassa virus GP2 recognized
either peptide P2, P3, or P4. The absence of a proliferative
response could be due to a low frequency of specific
memory CD4+ T-cells, or a major histocompatibility com-
plex class II (MHC-II) background not allowing for pre-
sentation of the respective peptides. To this end, we
performed an epitope prediction with the software ProPred,
using the sequences of P2, P3, and P4 and the MHC-II
alleles currently available for analysis. Table 4 shows that
for those alleles for which a virtual matrix is available, therewas a good correlation between experimentally observed
proliferation and prediction of epitopes. Only in one case
(donor #10) no significant proliferation was observed de-
spite prediction of an epitope.Discussion
Evidence for the importance of T-cell immunity in
human Lassa virus infection is so far largely indirect.
Lassa fever patients are viremic throughout the acute phase
of the disease in the presence of high titered, non-neutral-
izing antibodies (Johnson et al., 1987) and develop low-
titered neutralizing antibodies only late in convalescence,
that is, 3 to 4 months after the acute phase (Tomori et al.,
1987). The virus-neutralizing activity of these sera seems
to be strain specific (Jahrling et al., 1985). A strong CD4+
memory T-cell response against the nucleoprotein of Lassa
virus was recently shown in persons living in a Lassa-
endemic region in West Africa, independent of the pres-
ence or titer of anti-Lassa antibodies and in the proven
absence of a Lassa virus reinfection during the past 6 years
(ter Meulen et al., 2000).
Another line of evidence for the dominance of T-cells




    
Fig. 2. Reactivity of TCC 53 with stimulatory peptides derived from the sequence of Lassa virus, strain Josiah, and of the African arenavirus Mopeia. Presumed
fusion peptide (aa 276–298) is boxed. Bold lines indicate stimulatory peptides P2, P3, and P4. Numbers below alignment indicate aa positions in Josiah-GPC.
Amino acids that differ between Josiah and Mopeia are boldface. ‘‘:’’ Denotes conservative amino acid exchanges.
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guinea pigs with the Lassa-related, presumably nonpatho-
genic East-African arenavirus Mopeia, or the Old World
arenavirus lymphocytic choriomeningitis virus (LCMV)
confers immunity against Lassa fever (Jahrling and Peters,
1986; Kiley et al., 1979). In the guinea pig, this protection
was shown to be mediated by CD8+ cytotoxic cells, but
not serum. Recombinant vaccinia viruses and VEE repli-
cons expressing Lassa virus structural proteins (Fisher-
Hoch et al., 2000; Pushko et al., 2001) have also conferred
partial or full protection against disease, without neutraliz-
ing antibody activity being detectable in the sera of these
animals either after immunization or after challenge. Be-
cause Lassa virus strains vary up to 15% in their amino
acid sequence, the cross-protection of recombinant Lassa
vaccines against heterologous strains is an important issue
that has not yet been addressed in challenge experiments.
However, 30% of mice immunized intragastrically with an
attenuated salmonella strain expressing the Lassa virus
nucleoprotein were protected against a lethal LCMV chal-
lenge (Djavani et al., 2001), and cross-reactive cytotoxic
CD4+ T-cells against the LCMV-glycoprotein 2 could be
induced in mice by immunizing with a recombinant
vaccinia virus expressing the Lassa-glycoprotein precursor
GPC (La Posta et al., 1993). It was speculated that this
type of cells could generally be involved in cross-protec-tive immunity against heterologous arenavirus infections.
Taken together, the above outlined observations and
experiments imply that the cellular immunity plays the
major role in resolution of acute Lassa virus infection and
an important role in prevention of reinfection, with strong
CD8+ and CD4+ T-cell responses being induced by the
virus.
We show here, that persons from an endemic area with
strong CD4+ T-cell responses against the nucleoprotein of
Lassa virus, strain Josiah, also display strong responses
against the glycoprotein 2 (GP2), which is the most
conserved protein in all Lassa virus strains (Bowen et
al., 2000) and also the most conserved protein between
Old and New World arenaviruses (Charrel et al., 2002;
Weber and Buchmeier, 1988). As described for the nucle-
oprotein before, we observed T-cell reactivity against GP2
in Lassa antibody-positive and negative persons (ter Meu-
len et al., 2000). GP2 reactive T-cell clones generated
from one lymphocyte donor showed DR-restriction and
were of the Th1 phenotype, as we reported for T-cell
clones reactive with the nucleoprotein of Lassa virus. The
epitopes for five of the seven GP2-specific TCC were
mapped to a stretch of 20 aa, spanning a hydrophobic and
helical region in the N-terminal part of GP2, with four
clones recognizing an epitope defined by amino acids
289–301 and another clone reactive with the overlapping
Fig. 3. Freshly isolated PBMC of two donors were stimulated with recGP2
of Lassa virus, strain Josiah, or peptides P2, P3, and P4, spanning the
presumed fusion region. Assays were run in triplicate, standard error bars
are shown.
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has been predicted by computer modeling and experimen-
tal data (fusion of artificial liposomes) to mediate fusion
of the viral and cellular membranes during the infection
process (aa 276–298, Glushakova et al., 1990). AlignmentTable 4
Reactivity of PBMC to stimulatory peptides spanning the presumed fusion peptid
(TEPITOPE analysis)
Donora MHC-II (DR)b
28e DRB1*0101f, *0301 DRB3*0301g
1 DRB1*0102, *1303 DRB3*0101
11 DRB1*1102, *1503 DRB3*0301 DRB5*0101
8 DRB1*1101, *– DRB3*02XX
18 DRB1*0102, *1303 DRB3*0101
10 DRB1*0901, *1503 DRB4*01XX DRB5*0101
5 DRB1*1301, *– DRB3*0101 DRB3*02XX
a Numbering of lymphocyte donors as in Table 1.
b Because all GP2-specific TCC are DR-restricted, only epitopes for DR-alleles w
c Proliferation index of PBMC stimulated with peptides P2 (PGGYCLTRWMLIE
VAKCNEKHDEE). All assays run in triplicate, a P.I. z 2 is considered significa
d Predictions of optimally binding peptides within the postulated fusion domain o
e Donor No. 28 served as donor for the generation of P2, P3and P4 specific TCC
f Underlined allels: MHC-II epitopes predicted by TEPITOPE.
g Allels in italics: No TEPITOPE prediction possible for these alleles.of this region reveals a high degree of homology in all
arenaviruses, compared to an overall homology between
Old World (OW) and New World (NW) arenaviruses of
36.5–45.7% for GPC and approximately 60% similarity
for GP2 (Charrel et al., 2002). The first six amino acids of
the presumed fusion peptide (PGGYCL, aa 276–281) are
100% conserved in all Old and New World arenaviruses,
and overlap with a CD8+ T-cell epitope of Lymphocytic
Choriomeningitis virus for H-2Db-mice (SGVENPG-
GYCL, Ciatto et al., 2001). The following amino acids
282–288 are only up to 50% conserved (chemical iden-
tity), whereas aa 289–301 are 100% conserved in all Old
World arenaviruses and 92% conserved between Old and
New World arenaviruses of clades B and some of clade A.
It thus appears that the human CD4+ T-cell epitope (289–
301) is located in a region of GP2 that is most likely
evolutionary highly conserved because of its functional
importance. Interestingly, the third CD4+ epitope on GP2
(aa 394–406) partially overlaps with an epitope recog-
nized by cytotoxic CD4+ T-cells of H-2k mice (La Posta
et al., 1993).
Localization of human CD4+ T-cell epitopes in con-
served regions of viral proteins has been reported before. In
hepatitis C virus infection, dominant, promiscuous, and
highly conserved CD4+ T-cell epitopes have been identified
on the nonstructural proteins NS3 and NS4 (Diepolder et
al., 1997; Lamonaca et al., 1999). Dominant CD4+ epitopes
were also shown to be present in highly conserved, func-
tional domains (transcription activation domain) of the
Human Papillomavirus E2 protein (de Jong et al., 2002),
in conserved regions of the gag and pol proteins of HIV-1
(van der Burg et al., 1999; Wilson et al., 2001), the VP4
and VP2 proteins of Coxsackievirus B4 (Marttila et al.,
2002), the adenovirus capsid protein hexon (Olive et al.,
2002), and the NS3 of Dengue virus. In the latter, CD4+
clones cross-reactive between different serotypes were also
proven to be cytotoxic (Kurane et al., 1998). It thus appearse of Lassa virus GP2, in comparison with MHC-II-based epitope prediction
P2 P3 P4c TEPITOPE predictiond
TCC TCC TCC WMLIEAELK
neg. neg. neg. no epitope
2,6 neg. neg. WMLIEAELK
2,6 1,9 neg. WMLIEAELK, FGNTAVAKC
neg. neg. neg. no epitope
neg. neg. 1,5 WMLIEAELK
neg. 1,5 neg. no epitope
ere computed.
AELKCFG), P3 (RWMLIEAELKCFGNTAVAKC) or P4 (ELKCFGNTA-
nt.
f GP2 of Lassa virus, strain Josiah.
(see Table 1).
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on epitopes of viral proteins that are highly conserved
because of their functional importance is a common theme.
Obvious advantages could be cross-protection against dif-
ferent viral variants and strains, which might vary consid-
erably in other parts of their proteins, as well as possibly
avoiding the development of CD4+ T-cell escape mutants
in persistent infections such as Hepatitis C (Wang and
Eckels, 1999).
Dominant CD4 T-cell epitopes located in conserved
regions of viral proteins are often also promiscuous
epitopes, being presented by a wide range of different
MHC-II molecules (Diepolder et al., 1997; Lamonaca et
al., 1999; Olive et al., 2002; van der Burg et al., 1999;
Wilson et al., 2001). To this end, we stimulated PBMC
from six MHC class-II-typed donors directly with the
three peptides comprising the CD4+ T-cell epitopes in the
fusion region of GP2. Experimental data were compared
to computer-generated prediction of epitopes for the given
HLA alleles. There was a good correlation with epitope
prediction and only two of the donors showed a signif-
icant proliferation. Their HLA-DR alleles predicted to
present the peptides were DRB1*1101 and DRB5*0101,
compared to DRB1*0101 of the donor from which the
epitope defining TCC were derived. In this small series,
we did therefore not observe very promiscuous binding of
the epitopes; however, the assay might be too insensitive
too pick up a low number of memory T-cells. The
frequency of the above alleles has been estimated at
23%, 17%, and 13% for the population of African
descent and 17%, 24%, and 20% for the Caucasian
population, respectively (Sanchez-Mazas, 2001; Zachary
et al., 2001).
The degree of conservation of immunodominant T-cell
epitopes or MHC binding regions between different virus
strains will be pivotal for cross-protective immunity in a
predominantly T-cell controlled infection such as Lassa
fever. Because expression of both glycoproteins GP1 and
GP2 from recombinant vectors is necessary and suffi-
cient for protection of nonhuman primates against Lassa
virus challenge, our finding of highly conserved CD4+
T-cell epitopes in GP2 provides first evidence that a
recombinant vaccine may offer cross-protection on the
basis of a T-cell response. Furthermore, the identified
CD4 epitopes are also highly conserved in clade B of
the New World arenaviruses, which contain the South
American viruses causing hemorrhagic fever (Guanarito,
Sabia, Junin, and Machupo). Interestingly, a highly
conserved epitope for monoclonal antibodies cross-reactive
with Old and New World arenaviruses is also located on
GP2 (Weber and Buchmeier, 1988; Ruo et al., 1991).
Further analysis of conserved T-cell epitopes on arenavirus
structural and nonstructural proteins might lead to the
design of an optimal recombinant vaccine, which offers
protection against all Old and New World arenaviruses
causing hemorrhagic fever in humans.Materials and methods
Study population
Individuals with a past exposure to Lassa virus were
identified during epidemiologic investigations in the Re-
public of Guinea, West Africa, based on seropositivity or T-
cell reactivity with the nucleoprotein of Lassa virus (ter
Meulen et al., 2000). After obtaining informed consent,
blood samples were drawn for serology and preparation of
peripheral blood mononuclear cells (PBMCs). Seven per-
sons were chosen for this study, because their PBMC
strongly proliferated in response to stimulation with two
recombinant Lassa virus proteins NP and GP2. The donor of
the PBMC from which the GP2-specific T-cell clones (TCC)
were derived serves as a positive control in all T-cell assays
since 1997.
Detection of Lassa virus antibodies with indirect
immunofluorescence and ELISA
In the BSL4 facility of the University of Marburg, Lassa
virus (Josiah strain, JOS), was grown in Vero cells (ATCC
CCL 81), propagated in DMEM medium supplemented
with 5% fetal calf serum. For indirect immunofluorescence,
a standard procedure was performed as described previ-
ously (ter Meulen et al., 1998). To detect low-titer anti-
bodies that might be missed in IIF when testing sera at a
dilution of 1:20 or higher, an ELISA was also employed.
Lassa virus was grown in several large flasks (75 cm2) for
up to 1 week, and the supernatant was cleared from
floating cells by centrifugation at 1000  g for 30 min.
It was then pelleted through a 10-ml sucrose (20% w/v)
cushion in an SW28 rotor at 20.000 RPM for 2 h. The
pellets were resuspended in TNE buffer and subjected to 30
kGy of Co60 g-irradiation for inactivation, which was
tested by two blind passages of the inactivated material
in cell culture. The protein content of the inactivated virus
solution was adjusted to 100 Ag/ml and stored at 80 jC
until further use. NUNC-Maxisorp plates were coated with
a diluted virus solution of 10 Ag/ml overnight at 4 jC,
washed once with PBS/Tween 0.5% and blocked with
PBS/5% skimmed milk powder for 1 h. For each serum,
a negative control well was coated with uninfected Vero-
cell supernatant, cleared of floating cells. Human sera were
diluted (1:100) in PBS/5% skimmed milk and pipetted onto
the plate. After an incubation of 1 h at room temperature
and six washes (PBS/0.5% Tween20), conjugate (goat-anti-
huIgG-HRP, DIANOVA) was added in a dilution of 1:800
for 1 h; after six washes, the substrate (ABTS, KPL, MD,
USA) was added and the plate incubated for 30 min at 37
jC. Optical densities (OD) were read after 30 min at 405
nm. Sera were regarded positive if the OD ratio of the
virus-coated over the uninfected supernatant-coated well
was z2 (ratio A), and z2 times the OD of the negative
control serum (ratio B). The numerical value of ratio A is
J.ter Meulen et al. / Virology 321 (2004) 134–143 141given in Table 1. ELISA assays were run in duplicate
wells.
Cloning, expression, and purification of a C-terminally
truncated recombinant Lassa virus (JOS) glycoprotein 2
(recGP2)
The glycoprotein 2 (GP2) of arenaviruses is a type-I
transmembrane protein, which is generated in infected cells
through cleavage of the glycoprotein precursor GPC by the
cellular subtilase SKI-1/S1P (Lenz et al., 2001). To im-
prove its recombinant expression and solubilization in E.
coli, a C-terminally truncated form of the gene of GP2
(encoding for the luminal domain) was reverse transcribed
and PCR-amplified from Lassa virus RNA extracted from
infected Vero cell culture supernatant. The PCR fragment
was cloned via restriction-site containing primers (BamHI,
HindIII) in the procaryotic expression vector pQE30 (Qia-
gen, Hilden, Germany), resulting in expression of aa 1–
168 of GP2 (corresponding to aa 260–427 of the glyco-
protein precursor GPC). The abundantly overexpressed
protein was extracted from insoluble inclusion bodies with
8 M urea and purified by Ni-chelate affinity chromatogra-
phy (The QIAexpressionist, 1992). After purification
(>99% as estimated from Coomassie stained SDS-PAGE
gels), the protein was dialyzed against phosphate-buffered
saline for 48 h at 4 jC. The concentration was determined
photometrically and adjusted to 10 Ag/ml. The protein
solution was passed through a 0.2-Am filter and stored in
1.0-ml aliquots at 70 jC until further use. The cloning,
expression, and purification of the recombinant nucleopro-
tein of Lassa virus has been described elsewhere (ter
Meulen et al., 1998).
Synthesis of overlapping peptides comprising aa 9–168 of
the Lassa virus glycoprotein GP2, strain Josiah
For T-cell epitope mapping, a set of twenty-one 20-mer
peptides with 13 amino acids overlap was designed (span-
ning the sequence of the Lassa virus GP2 from amino acid
9–168) and synthesized using pin technology (Mimotopes
Pty Ltd, Clayton, Australia).
Major histocompatibility complex class II typing of
PBMC-donors
HLA class II analysis was performed after extraction of
DNA with phenol/chloroform from PBMCs. Amplification
of the HLA class II exons for DRB1, DRB3, DRB4, DRB5,
DQB1, DQA1, and DPB1 loci was performed by PCR as
described with locus-specific biotinylated primers as de-
scribed previously (Erlich et al., 1991; ter Meulen et al.,
2000). MHC class II alleles were determined as Donor #28:
DRB1*0101,0301. DRB3*0301. DQA1*0101,0101.
DQB1*02 ,0501 . Donor #1 : DRB1*0102 ,1303 .
DRB3*0101. DQA1*0101,05. DQB1*0301,0501.DPB1*0201,2601. Donor #11: DRB1*1102,1503.
DRB3 * 0 3 0 1 . DRB5 * 0 1 0 1 . DQA1 * 0 1 0 2 , 0 5 .
DQB1*0301,0602. DPB1*0101,*0402. Donor #8:
DRB1*1101 , . DRB3*02XX . DQA1*0102 , 0 5 .
DQB1*0301 ,0609 . DPB1*0101 , – . Donor #18 :
DRB1*0102,1303. DRB3*0101. DQA1*0101,05.
DQB1*0301,0501. DPB1*0201,2601. Donor #10:
DRB1*0901 , 1503 . DRB4*01XX . DRB*0101 .
DQA1*0102,03. DQB1*02XX,0602. DPB1*0101,– . Do-
no r # 5 : DRB1*1301 , – . DRB3*0101 , 02XX .
DQB1*0301,0603. DPB1*0201,1701.
Proliferation of PBMC and generation of GP2-specific
T-cell lines and clones
Procedures for the generation of nucleoprotein-specific
T-cell clones have previously been described (ter Meulen
et al., 2000). Briefly, 105 PBMC were stimulated with
recombinant GP2 (10 Ag/ml each), or with phytohemag-
glutinin (PHA, 2 Ag/ml), and [3H]thymidine incorporation
was measured by liquid scintillation spectrometry. In
parallel to proliferation assays, cultures showing prolifera-
tion microscopically were further stimulated with antigen
and 5 days thereafter propagated by supplementation with
10 U/ml IL-2. For secondary stimulation with GP2, 5 
104 cells of the primary T-cell lines were used. MHC II
haplotype-matched, g-irradiated PBMC (1  105) from
healthy European donors served as antigen-presenting
cells. To test whether GP2 was presented to TCC by DR
or DQ, supernatants of the hybridomas L243 (anti-DR,
Lampson and Levy, 1980) or Tu22 and Tu169 (anti-DQ,
Pawelec et al., 1985) were added during proliferation
assays, respectively.
In addition, PBMCs freshly obtained from six of the West
African donors were stimulated directly with three single
peptides (P2, P3, and P4) that span the presumed fusion
peptide of GP2, at a concentration of 1 Ag per individual
peptide as previously described (ter Meulen et al., 2000).
The ratio of the mean proliferative response to the
recombinant proteins over the negative control is given as
proliferative index (PI). The proliferation was regarded as
specific if the response to the recombinant proteins (or
peptides) exceeded that of the negative control plus three
times the standard deviation. Proliferation assays were run
in triplicate unless otherwise indicated.
T-cell epitope mapping with TCC using overlapping
synthetic peptides
Synthetic peptides (1 mg) were dissolved in 10 Al of
DMSO and brought to a final volume of 1 ml to create a
stock solution of 1 mg/ml. For cell culture, this stock
solution was further diluted in RPMI to end concentrations
of 10–0.001 Ag/ml. At these dilutions, the traces of DMSO
were found to influence neither proliferation nor cytokine
production, as pretested in mixing assays (data not shown).
rology 321 (2004) 134–143Cytokine assays
Measurement of cytokines in cell culture supernatants
was performed as previously described (ter Meulen et al.,
2000). Briefly, supernatants from cultures parallel to those
used for the determination of proliferation were harvested
after 3 days, stored at 20 jC, and cytokines were quan-
tified using cytokine-specific ELISA. Recombinant human
cytokines were used as reference standards (IL-4 and IFN-g
from Pharmingen, Hamburg, Germany) and the following
mAb pairs were used for capture and detection: IFN-g:
NIB42/biotinylated 4S.B3; IL-4: IL4–1/biotinylated MP4-
25D2 (all mAbs from Pharmingen). The working sensitivity
of all ELISA assays was shown to be 50 pg/ml.
Prediction of CD4 T-cell epitopes for individual MHC-II
alleles
For MHC class-II binding peptide prediction, the graph-
ical web tool ‘‘ProPred’’ was used (Singh and Raghava,
2001). This algorithm employs virtual MHC-II matrices
based on pocket profiles (TEPITOPE, Sturniolo et al.,
1999), which provide a detailed model in which the contri-
bution to binding of each amino acid (ligand) with each
pocket/position (HLA binding cleft) is quantified. Virtual
matrices are formed by assigning and combining pocket-
specific quantitative binding values derived from one HLA
allele to other alleles via HLA sequence comparison and
extrapolating from experimental data, thereby enabling
prediction of peptide ligands for a broad range of MHC-II
alleles (promiscuous peptides). Presently prediction of pep-
tide binders is possible for 51 MHC-II alleles (http://
www.imtech.res.in/raghava/propred). For our analysis, the
standard settings of the program were used (threshold 3%).
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